

Navigation

Pink Sheet 
Informa Pharma Intelligence

Scrip 
Informa Pharma Intelligence

In Vivo 
Informa Pharma Intelligence

Medtech Insight 
Informa Pharma Intelligence

Generics Bulletin 
Informa Pharma Intelligence


HBW Insight 
Informa Pharma Intelligence

PharmaIntelligence 
Informa

Menu



Each product has a Menu that appears horizontally near the top of the screen and continues to display when scrolling. (Note that on mobile devices the menu is located in the upper left near the product logo.) In addition to core topic areas, you will find special links like Featured Topics, regulatory and commercial data trackers, and exclusive editorial features.



1 Hover over the text to expand the tab and click on the menu items to navigate to topic pages and features.

2 For one-stop access to information about the publications, RSS feeds, the pdf library and quick contact links, look under **More**

3 To access **My View**, click the button on the right side of the menu bar.

Topic Pages

Click on a **Topic** from the **Menu** to explore the Topic

Drug Reviews 1 Set Alert for Drug Reviews

Latest From Drug Review

16 Dec 2020 | ANALYSIS

Tale Of Two Adcomms: US FDA Handling Of Entresto Data May Have Helped Avoid Aducanumab's Fate
By [Sue Sutter](#)

Review divisions strongly encouraged filing of both the Novartis and Biogen drugs despite trials that missed their primary endpoints; with the heart failure drug, the agency took a more even-handed approach to presenting the data and was commended for its willingness to look beyond the [Advisory Committees](#) | [Drug Review](#)

10 Nov 2020 | ANALYSIS

Pandemic-Affected Trials Will Need Same Exploratory Analyses That US FDA Used To Save Aducanumab
By [Sue Sutter](#)

Use of exploratory methods to understand as much as possible from the two Alzheimer's disease drug trials that were terminated early for futility is the same type of 'innovative thinking' that will be needed to salvage information from neuroscience trials interrupted by the COVID-19 [Advisory Committees](#) | [Drug Review](#)

10 Nov 2020 | ANALYSIS 2

PDUFA VII: Human Factors Review, Finance Flexibility, REMS, And Manufacturing Get Attention
By [Derrick Gingery](#)

User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement. [User Fees](#) | [Drug Review](#)

1 Set an **Alert** from **Topic Pages** with “1-click” – and whenever new content is published about your topic, an email alert will be delivered to you. When you set an alert, the alert icon will change state to a filled in appearance so you can easily see where you have set your alerts while on Topic pages.



2 **Bookmark** any article with “1-click” on the bookmark icon. When an article is bookmarked, the bookmark icon changes state to a filled in appearance so it is easy to see which articles have been bookmarked.

Articles you bookmark will be saved for you under **My Account** (located on the upper right of the pages) where you can go to access them at any time.

Article Pages

Across the top and bottom of every **article page** there is a toolbar to share, save, or follow up on the article.

TAGS: Immune Disorders | FDA | Companies

1 ASK THE ANALYST  2 EMAIL  3 PRINT  4 BOOKMARK  5 SHARE  

Gilead Gives Up On Galapagos's Filgotinib In RA

Belgian Biotech's Stock Battered

16 Dec 2020 | NEWS



by Kevin Grogan

kevin.grogan@informa.com

Executive Summary

ADVERTISEMENT

JUNE 23, 2021
**FY 2021 GENERIC
DRUG SCIENCE
AND RESEARCH
INITIATIVES
PUBLIC WORKSHOP**
REGISTER NOW
This conference is FREE and part of the SBIA Regulatory Education for Industry (REdI) series.



- 1 Click **ASK THE ANALYST** to access the Ask the Analyst service (for subscribers).
- 2 Click **EMAIL** icon to fill out a simple form to share the article by email.
- 3 Click the **PRINT** icon to print the article to hard copy or pdf.
- 4 Click the **BOOKMARK** icon to save the article to your Bookmarked Articles listing which is located under **My Account**.
- 5 Click the **LINKED IN** or **TWITTER** icons to share the article with your social networks.

Article Pages

To make it quick and easy for you to find other relevant content, our Article pages have numerous RELATED CONTENT links

1 TAGS: [OTC Drugs](#) | [Coronavirus COVID-19](#) | [Sales & Earnings](#) | [ASK THE ANALYST](#) | [EMAIL](#) | [PRINT](#) | [BOOKMARK](#) | [SHARE](#)


Unilever Extends Dove Into OTC Sanitizer Space And Its Hygiene Product Sales Increase 19%

27 Oct 2020 | NEWS

by Eileen Francis
eileen.francis@informa.com

Executive Summary

Growing consumer demand for OTC hand sanitizers driven by the pandemic prompted Unilever to extend its iconic soap brand Dove into the antibacterial market with a hand sanitizer line promoted also to moisturize skin.



2 **Related Content**

HBW INSIGHT
P&G Health, Hygiene Brands Ride Consumer 'Trust' To Sales Growth Amid Pandemic Uncertainty
20 Oct 2020

HBW INSIGHT
Unilever H1 Benefits From Sanitizer Blitz; Leadership Expects Lasting Hygiene 'Preoccupation'
27 Jul 2020

Related Content

HBW INSIGHT
P&G Health, Hygiene Brands Ride Consumer 'Trust' To Sales Growth Amid Pandemic Uncertainty
20 Oct 2020

Topics

- SUBJECTS
- > [OTC Drugs](#)
 - > [Coronavirus COVID-19](#)
 - > [Sales & Earnings](#)
 - > [Advertising, Marketing & Sales](#)
 - > [Business Strategies](#)
 - > [Commercial](#)
 - > [Companies](#)
 - > [Cosmetics](#)

REGIONS

- > [Europe](#)
 - > [Netherlands](#)
 - > [North America](#)
 - > [United States](#)
- > [International](#)

CONSUMER MARKET AREA

- > [Beauty](#)
- > [Health](#)

INDUSTRIES

- > [Consumer](#)

Related Companies

- > [Unilever PLC](#)

1 TAGS at the top and bottom of each article quickly show main topics of article and link to more on those topics.

2 RELATED CONTENT links along the right of each article page provide quick links to related topics and sub-topics; related articles; related companies; related deals; and key documents. Articles also have links to related stories/content within the article itself when relevant.

For More Information...



If you still have questions about how to access or use any of our products, or to schedule live training, please contact **Client Services** at:

Phone:

- ❖ US: 888-670-8900 or +1 212-600-3520
- ❖ UK: +44 (20) 805 20700

clientservices@pharmaintel.informa.com